Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Declines By 46.2%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 23,500 shares, a decline of 46.2% from the January 31st total of 43,700 shares. Based on an average trading volume of 197,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.6% of the shares of the stock are sold short.

Aptevo Therapeutics Trading Up 6.4 %

Shares of NASDAQ:APVO opened at $3.82 on Friday. The business’s fifty day moving average price is $4.26 and its two-hundred day moving average price is $211.69. Aptevo Therapeutics has a fifty-two week low of $3.01 and a fifty-two week high of $399.60.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research note on Monday, December 9th. They set a “sell” rating for the company.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.